Your browser is no longer supported. Please, upgrade your browser.
AMGN Amgen Inc. daily Stock Chart
Amgen Inc.
IndexS&P 500 P/E20.72 EPS (ttm)7.41 Insider Own0.10% Shs Outstand760.32M Perf Week-5.05%
Market Cap116.72B Forward P/E14.54 EPS next Y10.56 Insider Trans-9.99% Shs Float759.13M Perf Month-2.24%
Income5.71B PEG1.85 EPS next Q2.41 Inst Own82.50% Short Float1.27% Perf Quarter-3.49%
Sales20.58B P/S5.67 EPS this Y0.90% Inst Trans-0.30% Short Ratio2.99 Perf Half Y-4.76%
Book/sh34.83 P/B4.41 EPS next Y10.27% ROA8.20% Target Price179.47 Perf Year32.16%
Cash/sh35.67 P/C4.30 EPS next 5Y11.17% ROE22.40% 52W Range112.79 - 172.75 Perf YTD-2.63%
Dividend3.16 P/FCF20.11 EPS past 5Y8.20% ROI10.20% 52W High-10.44% Beta0.52
Dividend %2.06% Quick Ratio5.10 Sales past 5Y6.50% Gross Margin80.70% 52W Low37.18% ATR3.09
Employees17900 Current Ratio5.50 Sales Q/Q11.30% Oper. Margin37.00% RSI (14)42.86 Volatility2.22% 1.89%
OptionableYes Debt/Eq1.14 EPS Q/Q50.70% Profit Margin27.70% Rel Volume0.58 Prev Close153.52
ShortableYes LT Debt/Eq1.13 EarningsJul 28 AMC Payout34.90% Avg Volume3.23M Price154.72
Recom2.40 SMA20-1.70% SMA50-3.09% SMA200-0.60% Volume1,550,412 Change0.78%
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Apr-15-13Reiterated Barclays Equal Weight $90 → $105
Apr-08-13Reiterated RBC Capital Mkts Outperform $95 → $105
Jan-25-13Upgrade Argus Hold → Buy $96
Jun-30-15 02:43PM  Why is Celgene So Darn Expensive? at
01:18PM  Citigroup Still Says Sell AbbVie at
10:43AM  Is Celgene's Juno Deal a Boon or a Boondoggle? at
Jun-29-15 02:44PM  Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent
Jun-27-15 06:02PM  Biotech Short-Sellers Prefer Amgen To Gilead Sciences
Jun-25-15 12:44PM  Five Best Stocks to Buy According To Quant Billionaires at Insider Monkey
09:30AM  The Zacks Analyst Blog Highlights: BioMarin, Vical, Epizyme, Amgen and Medicines Co - Press Releases
Jun-24-15 08:44AM  Biotech Stock Roundup: BioMarin Jumps on Dwarfism Data, Vical Plunges on Vaccine Data - Analyst Blog
07:51AM  Inside Kite Pharma's 100% run
Jun-23-15 09:54PM  Amgen Dazzles With a Duo of Fresh Data at Investopedia
Jun-22-15 11:30AM  Amgen Presents Interim Data on Migraine Drug AMG 334 - Analyst Blog
01:03AM  Celimmune to Present Experimental Anti-IL-15 Antibody AMG 714 at 16th International Coeliac Disease Symposium PR Newswire
Jun-19-15 07:42PM  Better Dividend Stock: Amgen or Gilead Sciences? at Investopedia
04:05PM  Amgen Cancer Drug Vectibix Hits Phase III Primary Endpoint - Analyst Blog
04:00PM  Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine PR Newswire
03:44PM  Biotech bargain bin
01:41PM  Biotechs about to break out: Pro
12:48PM  Healthcare heats up in the summer
07:50AM  Early movers: HSY, RHT, SWHC, STT, CAG & more at CNBC
Jun-18-15 11:02PM  How Much Should Cancer Drugs Cost? at The Wall Street Journal
05:59PM  Amgen's cancer drug meets main goal in late-stage study
05:40PM  Biotech's big boost
04:26PM  Amgen cancer drug meets testing goal at MarketWatch
04:01PM  Results From Phase 3 Trial Show Vectibix┬« (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care PR Newswire
02:54PM  Biotech ETF Hits Record: How Much Higher Can It Go? at
12:27PM  Teva Migraine Drug Succeeds In Midstage Trial at Investor's Business Daily
Jun-17-15 12:10PM  Frozen forehead meets double chin at Financial Times
Jun-16-15 12:39PM  We've Only Seen This Contrarian Buy Signal One Other Time Since 2009 at Forbes
Jun-15-15 02:13PM  Biotech's Rally Has Long-Term Legs, Asserts S&P Capital IQ Director at TheStreet
08:05AM  Hot Atara snags licensing deal with leading cancer center at
Jun-14-15 05:12PM  Open Monoclonal Technology Announces OmniAb Alliance With Amgen Business Wire
Jun-12-15 08:00PM  IBD Market Wrap - 06/12/15
10:10AM  Stock Market News for June 12, 2015 - Market News
09:00AM  Steven Nissen, Conflicts Of Interest, And The New Cholesterol Drugs at Forbes
03:05AM  Edited Transcript of AMGN presentation 11-Jun-15 3:40pm GMT
Jun-11-15 04:30PM  Merck (MRK) Presents Multiple Biosimilar and Diabetes Data - Analyst Blog
03:42PM  Why Is Amgen Rising And Regeneron Falling? at
01:41PM  Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks
12:26PM  4 Stocks, 4 trades: BOX, FDX & more
08:59AM  Krispy Kreme pops; Lululemon founder sells stake; Nike inks NBA deal
08:10AM  Retail sales rebound; Nike's big NBA score; LA minimum wage hike
08:02AM  New Migraine Drugs Could Ease Investors' Headaches at Investor's Business Daily
01:11AM  FDA Panel Backs Amgens Cholesterol-Lowering Drug at The Wall Street Journal
Jun-10-15 09:32PM  This Trial Could Be Worth Billions to Amgen at Investopedia
08:10PM  Is This Johnson & Johnson's Next Blockbuster? at Investopedia
07:16PM  FDA Panel Recommends Amgen's Cholesterol-Lowering Drug at The Wall Street Journal
06:10PM  FDA panel backs Amgen cholesterol drug for some patients
05:52PM  After-hours buzz: Box, Krispy Kreme, Nike & more at CNBC
05:35PM  Amgen Cholesterol Drug Repatha Wins FDA Panel Vote at Investor's Business Daily
05:27PM  FDA panel backs Amgen cholesterol drug for some patients at Los Angeles Times
04:37PM  FDA panel backs Amgen's cholesterol drug for high-risk patients Reuters
04:01PM  Amgen Cholesterol Drug Wins Panels Backing for Some Patients at Bloomberg
03:44PM  UPDATE 3-FDA panel backs Sanofi/Regeneron cholesterol drug with limits Reuters
03:26PM  Live Blog: FDA Panel For Amgen's Cholesterol Drug Repatha at Forbes
12:49PM  Why a FDA nod isn't enough for Regeneron shares at CNBC
10:52AM  FDA Panel Clears Product Path For Sanofi, Regeneron Pharmaceuticals
10:24AM  Biotech Stock Roundup: FDA Panel Recommends Regeneron's Praluent, SAGE Gains on Data - Analyst Blog
10:06AM  How to Trade the Stocks of Four Giants in the Health Care Industry at TheStreet
09:10AM  Netflix hits fresh 52-week high; Apple Music probe; HCC surges on merger
08:15AM  Wall Street's funk; Target's dividend slip up; Apple's antitrust problem
08:00AM  Amgen To Discuss Details Of Repatha (Evolocumab) Biologics License Application For The Treatment Of High Cholesterol PR Newswire
07:21AM  Two drugs target 'bad' cholesterol: CEO
Jun-09-15 06:09PM  Regeneron/Sanofi Cholesterol Drug Wins FDA Panel Vote at Investor's Business Daily
06:09PM  Regeneron Cholesterol Fighter Gets FDA Panel's Backing, 13-3
05:25PM  Cholesterol drug wars
05:00PM  Amgen's Repatha Briefing Document Gives Mixed Review - Analyst Blog
01:01PM  Battling 'bad' cholesterol
08:30AM  FDA weighs target population for Amgen cholesterol drug
08:00AM  Two Big Biotech ETFs
06:31AM  FDA targets 'bad' cholesterol drug
Jun-08-15 09:59PM  This Key Amgen Drug Is Setting a Precedent at Investopedia
04:49PM  FDA weighs best patient group for Amgen cholesterol drug at Los Angeles Times
04:00PM  Amgen To Present At The Goldman Sachs Global Healthcare Conference PR Newswire
10:28AM  FDA weighs best patient group for Amgen cholesterol drug
10:07AM  Amgen's Repatha effective; question is for which patients--FDA Reuters
09:11AM  Amgen Cholesterol Drug Faces Question From FDA Staff on Benefit at Bloomberg
12:08AM  FDA Queues Up Review of Anti-Cholesterol Drugs at The Wall Street Journal
Jun-07-15 09:40AM  New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels at 24/7 Wall St.
Jun-06-15 08:02AM  Are 4 Top-Rated IBD 50 Drug Stocks On Your Radar? at Investor's Business Daily
05:33AM  FDA Reviews Anti-Cholesterol Drugs at The Wall Street Journal
Jun-05-15 05:16PM  FDA weighs approval of first-in-class cholesterol drug
04:54PM  Regeneron/Sanofi Cholesterol Drug Under FDA Scrutiny at Investor's Business Daily
10:44AM  The Fight Against Cholesterol Heats Up; FDA Panel Considers Drugs from Regeneron, Amgen Next Week at
09:36AM  FDA Staff Says Sanofi Drug Cuts Cholesterol, Questions Benefit at Bloomberg
08:00AM  Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease PR Newswire
Jun-04-15 05:25PM  Fighting 'bad' cholesterol
11:59AM  Amgen Subpoenas a Journalist as it Fights a Shareholder Lawsuit at The Wall Street Journal
11:49AM  Cramer -- Why Intel's Deal for Altera Was Needed; Costco Is a Buy at TheStreet
Jun-03-15 04:41PM  Novartis tries to get U.S. ban lifted on sale of Neupogen copycat Reuters
12:43PM  Amgen, Novartis Battle in Court on Copycat Version of Neupogen at Bloomberg
11:34AM  Biotech Stock Roundup: ImmunoGen Soars on ASCO Data, Amgen Collaborates with Roche - Analyst Blog
09:59AM  Amgen: The Quiet Winner at
Jun-02-15 04:42PM  Roche Collaborates with Amgen for Immuno-Oncology - Analyst Blog
04:00PM  [video]Why Health Care Stocks Will Continue to Lead Market Higher at TheStreet
10:30AM  Merck's Keytruda under Priority Review for Lung Cancer - Analyst Blog
01:00AM  Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab PR Newswire
Jun-01-15 03:29PM  AstraZeneca Nearing Decision on Suicide-Linked Drug, CEO Says at Bloomberg
12:39PM  ImmunoGen, Bristol make strides in cancer battle at MarketWatch
10:37AM  Will Big Pharma Cancer Drug Collaborations Set The Stage For Lower Drug Costs? at Forbes
09:00AM  Amgen Presents Phase 3 Data At ASCO Showing Prolia┬« (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors PR Newswire
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patton Cynthia MSVP & CCOJun 02Sale157.064,530711,48216,571Jun 03 07:16 PM
Balachandran MadhavanEVP, OperationsMay 07Option Exercise55.7221,7501,211,94855,144May 11 04:56 PM
Balachandran MadhavanEVP, OperationsMay 07Sale157.8721,7503,433,69533,394May 11 04:56 PM
Tross Stuart ASVP, Human ResourcesApr 23Sale169.313,012509,96421,923Apr 24 04:53 PM
Harper Sean EEVP, Research & DevelopmentApr 22Sale171.5828,0004,804,24047,920Apr 23 05:04 PM
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM